Therefore, the molecular mechanisms underlying ITGB5's dysregulation in AD with depression is worthy of further investigation, which could provide valuable insights into new therapeutic targets for complex neurodegenerative and psychiatric disorders. This evidence concerns the gene ITGB5 and depressive symptom measurement.